Literature DB >> 7534303

v-Abl-mediated apoptotic suppression is associated with SHC phosphorylation without concomitant mitogen-activated protein kinase activation.

P J Owen-Lynch1, A K Wong, A D Whetton.   

Abstract

A temperature-sensitive mutant of the v-Abl protein has previously been shown to exhibit tyrosine protein kinase activity in Interleukin 3 (IL-3)-dependent IC.DP cells grown at the permissive temperature (32 degrees C) but not at the restrictive temperature (39 degrees C). These IC.DP cells are dependent on IL-3 for suppression of apoptosis at 39 degrees C, but at 32 degrees C cells will survive without added growth factor. Both IL-3 and v-Abl stimulated the tyrosine phosphorylation of SHC and GTPase-activating protein. However, while IL-3 stimulated similar levels of tyrosine phosphorylation in p46shc and p52shc, v-Abl preferentially phosphorylated p52shc, an event that occurred within 1 h of temperature switch. v-Abl also differentially associated with p46shc in a temperature-independent manner. In contrast, only IL-3 stimulated detectable increases in both myelin basic protein kinase and mitogen-activated protein (MAP) kinase kinase in in vitro assays, although in more specific MAP kinase activity assays a very slight increase in the activity of this enzyme was observed after 6 h at the permissive temperature. Time course studies suggest that phosphorylation and association of SHC with v-Abl is insufficient to lead to significant activation of MAP kinase and that activation of the MAP kinase kinase/MAP kinase pathway is not required for apoptotic suppression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7534303     DOI: 10.1074/jbc.270.11.5956

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt.

Authors:  G Kulik; A Klippel; M J Weber
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

2.  The carboxyl terminus of v-Abl protein can augment SH2 domain function.

Authors:  D Warren; A J Heilpern; K Berg; N Rosenberg
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

Review 3.  Kinase cascades regulating entry into apoptosis.

Authors:  P Anderson
Journal:  Microbiol Mol Biol Rev       Date:  1997-03       Impact factor: 11.056

4.  Inhibition of the Raf-1 kinase by cyclic AMP agonists causes apoptosis of v-abl-transformed cells.

Authors:  E M Weissinger; G Eissner; C Grammer; S Fackler; B Haefner; L S Yoon; K S Lu; A Bazarov; J M Sedivy; H Mischak; W Kolch
Journal:  Mol Cell Biol       Date:  1997-06       Impact factor: 4.272

5.  Disruption of the Shc/Grb2 complex during abelson virus transformation affects proliferation, but not apoptosis.

Authors:  Linda B Baughn; Naomi Rosenberg
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

6.  A novel pathway from phosphorylation of tyrosine residues 239/240 of Shc, contributing to suppress apoptosis by IL-3.

Authors:  N Gotoh; A Tojo; M Shibuya
Journal:  EMBO J       Date:  1996-11-15       Impact factor: 11.598

Review 7.  Biochemical and molecular mechanisms regulating apoptosis.

Authors:  K S Saini; N I Walker
Journal:  Mol Cell Biochem       Date:  1998-01       Impact factor: 3.842

8.  Temperature-sensitive transformation by an Abelson virus mutant encoding an altered SH2 domain.

Authors:  C A Mainville; K Parmar; I Unnikrishnan; L Gong; G D Raffel; N Rosenberg
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

9.  Ras complements the carboxyl terminus of v-Abl protein in lymphoid transformation.

Authors:  K Parmar; N Rosenberg
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

10.  Direct interaction of Jak1 and v-Abl is required for v-Abl-induced activation of STATs and proliferation.

Authors:  N N Danial; J A Losman; T Lu; N Yip; K Krishnan; J Krolewski; S P Goff; J Y Wang; P B Rothman
Journal:  Mol Cell Biol       Date:  1998-11       Impact factor: 4.272

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.